How does azacitidine work, and why does it hit normal blood cells too?
Azacitidine is a chemotherapy drug used for certain blood cancers and related blood disorders. It works in part by changing gene activity in cells (a process linked to DNA “methylation”). Because it affects cell growth and gene regulation, it can also slow or disrupt the production of blood cells that are normally made in the bone marrow, not only the abnormal cancer cells. This is why azacitidine commonly lowers blood counts in patients during treatment [1].
What happens to red blood cells (anemia)?
When azacitidine suppresses bone marrow activity, patients may develop anemia, which means there are fewer red blood cells to carry oxygen. Symptoms can include fatigue, weakness, shortness of breath, or dizziness. Clinicians monitor hemoglobin and red blood cell counts to manage this risk during therapy [1].
What happens to white blood cells (neutropenia/leukopenia)?
A common effect is a drop in white blood cells, especially neutrophils (neutropenia). With fewer neutrophils, patients can have a higher risk of infection. Because infections can become serious quickly when neutrophils are low, blood counts are checked regularly and clinicians may recommend preventive measures or prompt treatment if fever occurs [1].
What happens to platelets (thrombocytopenia)?
Azacitidine can also reduce platelet production. Low platelets (thrombocytopenia) can increase the risk of bruising and bleeding, and it can make procedures or injuries more dangerous. Treatment may require dose adjustments or supportive care depending on how low platelet counts fall [1].
How is this risk managed during treatment?
The standard approach is close monitoring of complete blood counts (CBCs) during each treatment cycle. If counts drop too much, clinicians may delay the next dose, reduce the dose, or provide supportive care such as transfusions (for anemia or bleeding risk) and infection precautions for low white counts [1].
When do blood-cell drops usually show up?
Bone marrow suppression typically affects blood counts over the course of treatment cycles, with changes often noticed during follow-up CBC testing. The pattern of recovery between cycles varies by patient, cancer type, baseline counts, and overall marrow function, so clinicians use trends to guide dosing decisions [1].
---
Sources:
[1] DrugPatentWatch.com – azacitidine related information (drug profile and related background): https://www.drugpatentwatch.com/